{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:27:51Z","timestamp":1793950071306,"version":"4.8.0"},"reference-count":59,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/13543784.2026.2748359","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:24:26Z","timestamp":1791725066000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers"],"prefix":"10.1080","volume":"35","author":[{"given":"Panagiotis Velissarios","family":"Stamatakos","sequence":"first","affiliation":[{"name":"General Hospital of Athens \u201cKorgialeneio Benakeio Hellenic Red Cross\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Fragkoulis","sequence":"additional","affiliation":[{"name":"General Hospital of Athens \u201cG. Gennimatas\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kontolatis","sequence":"additional","affiliation":[{"name":"General Hospital of Athens \u201cG. Gennimatas\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Gklinos","sequence":"additional","affiliation":[{"name":"General Hospital of Athens \u201cG. Gennimatas\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Kourouniotis","sequence":"additional","affiliation":[{"name":"General Hospital of Athens \u201cKorgialeneio Benakeio Hellenic Red Cross\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Dellis","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, Hospital of Athens \u201cAretaieion\u201d","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-026-04424-3"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70019"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.01.002"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.07.011"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2022.11.014"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012045.pub2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0111"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01883-7"},{"issue":"4","key":"e_1_3_5_12_1","first-page":"312","article-title":"European Association of Urology guidelines on renal cell carcinoma: 2024 update","volume":"85","author":"Ljungberg B","year":"2024","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: 2024 update. Eur Urol. 2024;85(4):312\u2013325.","journal-title":"Eur Urol"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.01.043"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.04.002"},{"key":"e_1_3_5_15_1","unstructured":"ClinicalTrials.gov. A study of Zanzalintinib in combination with nivolumab in clear cell renal cell carcinoma (EXPLORE-RCC). Identifier NCT05445258. [cited 2026 Aug]."},{"key":"e_1_3_5_16_1","unstructured":"ClinicalTrials.gov. Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma (NEOPAX). Identifier NCT05007782. [cited 2026 Aug]."},{"key":"e_1_3_5_17_1","unstructured":"ClinicalTrials.gov. Neoadjuvant pembrolizumab and Lenvatinib in patients with non-metastatic clear cell renal cell carcinoma. Identifier NCT04523272. [cited 2026 Aug]."},{"key":"e_1_3_5_18_1","unstructured":"ClinicalTrials.gov. PRE-surgical NEOadjuvant sandwich immunotherapy with HIF inhibiTion in renal cell carcinoma (PRENEOSHIFT-RCC). Identifier NCT06277258. [cited 2026 Aug]."},{"key":"e_1_3_5_19_1","unstructured":"ClinicalTrials.gov. Phase ii trial of Belzutifan and Pembrolizumab in clear cell renal cell carcinoma (BLAZE). Identifier NCT05139979. [cited 2026 Aug]."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020312"},{"key":"e_1_3_5_21_1","volume-title":"Edn. presented at the 41st EAU Annual Congress London","author":"Gontero P","year":"2026","unstructured":"Gontero P, Babjuk M, Burger M, et al. EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS), in EAU guidelines. In: Edn. presented at the 41st EAU Annual Congress London; EAU Guidelines Office; 2026. https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2020.09.007"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2021.0587"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194841"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000644"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00763"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.014"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00179"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(08)60731-9"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0022"},{"key":"e_1_3_5_31_1","unstructured":"ClinicalTrials.gov. Neoadjuvant enfortumab vedotin in upper tract urothelial carcinoma. Identifier NCT05868265. [cited 2026 Aug]."},{"key":"e_1_3_5_32_1","unstructured":"ClinicalTrials.gov. Gemcitabine and durvalumab in cisplatin-ineligible high grade upper tract urothelial carcinoma (ECOG-ACRIN EA8192). Identifier NCT04628767. [cited 2026 Aug]."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/23523735261417616"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674"},{"key":"e_1_3_5_40_1","unstructured":"ClinicalTrials.gov. Perioperative enfortumab vedotin plus pembrolizumab in cisplatin-eligible bladder cancer (KEYNOTE-B15\/EV-304). Identifier NCT04700124. [cited 2026 Aug]."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00050-1"},{"key":"e_1_3_5_42_1","unstructured":"ClinicalTrials.gov. Durvalumab tremelimumab and enfortumab vedotin for perioperative bladder cancer (VOLGA). Identifier NCT04960709. [cited 2026 Aug]."},{"key":"e_1_3_5_43_1","unstructured":"ClinicalTrials.gov. Erdafitinib and Cetrelimab as neoadjuvant treatment in cisplatin-ineligible MIBC (SOGUG-NEOWIN). Identifier NCT04383223. [cited 2026 Aug]."},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-026-01330-7"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010065"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010099"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00315"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00514-9"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01777"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35170"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2603878"},{"key":"e_1_3_5_52_1","unstructured":"ClinicalTrials.gov. Neoadjuvant leuprorelin and darolutamide in localized prostate cancer (coaction). Identifier NCT05716490. [cited 2026 Aug]."},{"key":"e_1_3_5_53_1","unstructured":"ClinicalTrials.gov. Neoadjuvant ADT plus darolutamide and pembrolizumab followed by adjuvant pembrolizumab in prostate cancer. Identifier NCT07027124. [cited 2026 Aug]."},{"key":"e_1_3_5_54_1","unstructured":"ClinicalTrials.gov. Neoadjuvant PARP inhibition followed by radical prostatectomy (Neptune). Identifier NCT05498272. [cited 2026 Aug]."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203330"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.026"},{"key":"e_1_3_5_57_1","unstructured":"ClinicalTrials.gov. Neoadjuvant Lu-177-PSMA-617 in patients with high risk localized prostate cancer (prelude). Identifier NCT06798558. [cited 2026 Aug]."},{"key":"e_1_3_5_58_1","unstructured":"ClinicalTrials.gov. Genomic biomarker-selected umbrella neoadjuvant study for high risk localized prostate cancer (guns). Identifier NCT04812366. [cited 2026 Aug]."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28648"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.11.016"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1796138"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2748359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2748359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2748359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:56:57Z","timestamp":1793948217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2748359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/13543784.2026.2748359"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2748359","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}